Seroconversion rate is 96.0% for measles
Objectives:
Despite the universal use of the two-dose trivalent measles-mumps-rubella (MMR) vaccine in the past two decades, outbreaks of these diseases still occur in countries with high vaccine uptake, giving rise to concerns about primary and secondary failure of MMR vaccine components. Therefore, this review article has been conducted.
What is the seroconversion and waning rate estimates for the measles, mumps and rubella components of MMR vaccines?
Study design:
This review article included 62 studies.